Conference Documents
- Session 1.1 – OMS History with tribute to Michael Pranzatelli – Wendy Mitchell
- Session 1.2 – OMS introduction and summary of last workshop – Ming Lim
- Session 1.3 – OMS Consensus Statement – Ming Lim, Mark Gorman, Wendy Mitchell, Pedro de-Alarcon
- Session 1.4 – OMSLife Registry Progress – initial discussion – Michael Michaelis
- Session 1.5 – OMS MultiNational Registry Progress – initial discussion – Mark Gorman
- Session 2.1 – Completion of European Trial Interim results – Gudrun Schleiermacher
- Session 2.2 – Past, Present, and Future: The Study of OMAS – Pedro DeAlarcon
- Session 2.3 – Late Cognitive and Adaptive Outcomes of Patients with Neuroblastoma-Associated Opsoclonus-Myoclonus-Ataxia-Syndrome (OMAS): A Report from the Children’s Oncology Group (COG) – Pedro DeAlarcon
- Session 3.1 – Detection of novel autoantibodies in children with OMS – Thais Armangue
- Session 3.3 – Mapping somatic B-Cell responses – lessons learnt from antibody mediated disorders – Adam Handel
- Session 4.1 – Overview of immunobiology of OMS – Jonathan Santoro
- Session 4.3 – New treatment horizons – Despina Eleftheriou, Great Ormond Street Hospital
- Session 4.4 – Transplants for autoimmune disease – Jennifer Clark, Rocky Mountain Hospital for Children
- Session 5.1 – PET-MRI in neuro-inflammatory conditions – Dr. Bernedetta Bodini – Paris
- Session 5.2 – Ultra-high field imaging in autoimmune encephalitis – Michael Eyre and David Carmichael, Kings College London
- Session 6.1 – Psychiatric manifestations of neuro-inflammatory conditions – Aaron Hauptman
- Session 6.2 – Anxiety – OMS – Morag McLeod
- Session 6.3 – OMS Abingdon 2022 reflection